PhaseBio Pharmaceuticals Inc

+0.20 (+6.94%)
Earnings Announcements

Phasebio Reports Q4 And FY20 Financial Results

Published: 03/15/2021 12:20 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Reports Fourth-quarter and Full-year 2020 Financial Results and Recent Business Highlights.
Qtrly Loss per Share $1.03.
Q4 Earnings per Share View $-0.71 -- Refinitiv Ibes Data (analyst estimates).
Cash and Cash Equivalents at Dec 31, 2020 Were $28.1 Million Versus $74.0 Million at Dec 31, 2019.
Revenue is expected to be $0.13 Million
Adjusted EPS is expected to be -$0.57

Next Quarter Revenue Guidance is expected to be $0.14 Million
Next Quarter EPS Guidance is expected to be -$0.56

More details on our Analysts Page.